Naltrexone

Generic Name
Naltrexone
Brand Names
Contrave, Embeda, Vivitrol
Drug Type
Small Molecule
Chemical Formula
C20H23NO4
CAS Number
16590-41-3
Unique Ingredient Identifier
5S6W795CQM
Background

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Indication

Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Associated Conditions
Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
Associated Therapies
-
Clinical Trials
Related News

Medication-Assisted Treatment for Youth With Substance Use Disorders

Phase 1
Completed
Conditions
Opioid Use Disorder
Opioid Dependence
Interventions
Drug: Naltrexone
First Posted Date
2015-11-01
Last Posted Date
2018-10-31
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
11
Registration Number
NCT02593474
Locations
🇺🇸

New York State Psychiatric Insitute, New York, New York, United States

🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity

Not Applicable
Completed
Conditions
Addiction
Interventions
Drug: Placebo
Drug: Amisulpride
Drug: Naltrexone
First Posted Date
2015-09-23
Last Posted Date
2015-09-23
Lead Sponsor
University of Zurich
Target Recruit Count
121
Registration Number
NCT02557984
Locations
🇨🇭

University Hospital, Zurich, Switzerland

The Effect of Regular Naltrexone Dosing on Disordered Gamblers

Phase 1
Completed
Conditions
Gambling
Interventions
Drug: Naltrexone
First Posted Date
2015-09-01
Last Posted Date
2022-06-01
Lead Sponsor
University of Calgary
Target Recruit Count
35
Registration Number
NCT02537197
Locations
🇨🇦

Opioid Dependency Program, Calgary, Alberta, Canada

The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism

Not Applicable
Completed
Conditions
Opiate Addiction
Interventions
Drug: Naltrexone
Drug: Clonidine
Drug: Lorazepam
First Posted Date
2015-02-12
Last Posted Date
2015-02-12
Lead Sponsor
Vilnius University
Target Recruit Count
60
Registration Number
NCT02362256
Locations
🇱🇹

Republic Vilnius University Hospital, Vilnius, Lithuania

Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM

Phase 2
Completed
Conditions
Binge Drinking
HIV
Interventions
Drug: Placebo
Drug: Naltrexone
First Posted Date
2015-01-05
Last Posted Date
2021-09-28
Lead Sponsor
University of California, San Francisco
Target Recruit Count
120
Registration Number
NCT02330419
Locations
🇺🇸

Center on Substance Use and Health, San Francisco, California, United States

Biomarkers of Injectable Extended Release Naltrexone Treatment

Phase 4
Completed
Conditions
Heroin Dependence
Opioid Dependence
Interventions
Drug: Naltrexone
First Posted Date
2014-12-24
Last Posted Date
2023-01-12
Lead Sponsor
University of Pennsylvania
Target Recruit Count
32
Registration Number
NCT02324725
Locations
🇺🇸

Center for the Studies of Addiction, Philadelphia, Pennsylvania, United States

Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders

First Posted Date
2014-12-22
Last Posted Date
2020-12-29
Lead Sponsor
Seattle Institute for Biomedical and Clinical Research
Target Recruit Count
31
Registration Number
NCT02322047
Locations
🇺🇸

VA Puget Sound Healthcare System, Seattle, Washington, United States

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function

Phase 1
Completed
Conditions
Cutaneous Nerves CNS Itch
Interventions
Drug: Clonidine
Drug: Naltrexone
First Posted Date
2014-10-20
Last Posted Date
2023-01-26
Lead Sponsor
University of Minnesota
Target Recruit Count
8
Registration Number
NCT02268448
Locations
🇺🇸

University of Minnesota Department of Dermatology, Minneapolis, Minnesota, United States

Trial of Naltrexone and Dextromethorphan for Gulf War Illness

Phase 2
Completed
Conditions
Gulf War Illness
Interventions
Drug: naltrexone
Drug: Dextromethorphan
First Posted Date
2014-08-01
Last Posted Date
2016-03-03
Lead Sponsor
East Carolina University
Target Recruit Count
60
Registration Number
NCT02206490
Locations
🇺🇸

Brody School of Medicine a East Carolina Univesity, Greenville, North Carolina, United States

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Oxycodone
Drug: Naltrexone
First Posted Date
2014-06-18
Last Posted Date
2016-04-04
Lead Sponsor
Pain Therapeutics
Target Recruit Count
17
Registration Number
NCT02165930
Locations
🇺🇸

Pfizer Investigational Site, Overland Park, Kansas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy